Display options
Cite
Gundel RH, Heuer HO, Letts LG. Is platelet activating factor (PAF) an important mediator in bronchial asthma?. Mediators Inflamm. 1992;1(6):367-9doi: 10.1155/S0962935192000541.
Gundel, R. H., Heuer, H. O., & Letts, L. G. (1992). Is platelet activating factor (PAF) an important mediator in bronchial asthma?. Mediators of inflammation, 1(6), 367-9. https://doi.org/10.1155/S0962935192000541
Gundel, R H, et al. "Is platelet activating factor (PAF) an important mediator in bronchial asthma?." Mediators of inflammation vol. 1,6 (1992): 367-9. doi: https://doi.org/10.1155/S0962935192000541
Gundel RH, Heuer HO, Letts LG. Is platelet activating factor (PAF) an important mediator in bronchial asthma?. Mediators Inflamm. 1992;1(6):367-9. doi: 10.1155/S0962935192000541. PMID: 18475485; PMCID: PMC2365369.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1992;1(6):367-9. doi: 10.1155/S0962935192000541.

Is platelet activating factor (PAF) an important mediator in bronchial asthma?.

Mediators of inflammation

R H Gundel, H O Heuer, L G Letts

Affiliations

  1. Department of Pharmacology Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT 06877 USA.

PMID: 18475485 PMCID: PMC2365369 DOI: 10.1155/S0962935192000541

Abstract

The development of selective PAF receptor antagonists may provide a novel approach to the treatment of human bronchial asthma. In preclinical animal models of human asthma, PAF receptor antagonists have been found to be efficacious in blocking antigen-induced changes in lung function. However, the majority of these models involve acute inflammatory events and transient changes in lung function and, therefore, their relevance to human asthma is questionable. In a recent study with a primate model of chronic airway inflammation and hyperresponsiveness, we have shown that treatment with a PAF receptor antagonist had no effect on reducing chronic inflammation and hyperresponsiveness. Similarly, recent studies in human asthmatics with PAF receptor antagonists have failed to show efficacy in blocking allergen-induced airway responses or to have any steroid sparing effects in patients with ongoing asthma. Thus, it seems that PAF may not be a key mediator which can be blocked and thereby provide therapy for bronchial asthma.

References

  1. J Lipid Mediat. 1991 Jul-Aug;4(1):39-44 - PubMed
  2. Br J Pharmacol. 1990 Jun;100(2):217-22 - PubMed
  3. Agents Actions Suppl. 1988;23:207-15 - PubMed
  4. Lancet. 1986 Jul 26;2(8500):189-92 - PubMed
  5. J Clin Invest. 1986 Dec;78(6):1701-6 - PubMed
  6. Eur J Respir Dis Suppl. 1986;146:277-84 - PubMed
  7. Lipids. 1991 Dec;26(12):1374-80 - PubMed
  8. Eur J Pharmacol. 1980 Jul 25;65(2-3):185-92 - PubMed
  9. J Appl Physiol (1985). 1989 Jul;67(1):406-13 - PubMed

Publication Types